Worth Venture Partners, LLC Adverum Biotechnologies, Inc. Transaction History

Worth Venture Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.75 - $1.26 $339,508 - $570,374	452,678 Added 136.49%	784,346 $588,000
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.33 $58,522 - $90,904	-39,015 Reduced 10.53%	331,668 $497,000
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $49,043 - $114,675	72,123 Added 24.16%	370,683 $589,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $47,769 - $481,676	49,760 Added 20.0%	298,560 $284,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $201,528 - $333,392	248,800 New	248,800 $425,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.